Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 940	$ 539
Operating expenses:
Research and development	118,245	70,620
General and administrative	28,021	24,517
Collaboration expense, net	30,646	19,945
Total operating expenses	176,912	115,082
Loss from operations	(175,972)	(114,543)
Other income:
Other income, net	363	1,955
Total other income, net	363	1,955
Net loss income before income taxes	(175,609)	(112,588)
Provision for income taxes	(3,608)	(575)
Net loss	(179,217)	(113,163)
Foreign currency translation adjustment	(27)	5
Unrealized loss on marketable securities	(11,799)	(383)
Comprehensive loss	$ (191,043)	$ (113,541)
Net loss per common share - basic	$ (2.32)	$ (1.51)
Basic weighted-average common shares outstanding	77,098,319	75,005,187
Net loss per common share - diluted	$ (2.32)	$ (1.51)
Diluted weighted-average common shares outstanding	77,098,319	75,005,187
Collaboration Revenue [Member]
Revenue:
Total revenue	$ 178	$ 202
Grant Revenue [Member]
Revenue:
Total revenue	$ 762	$ 337